Monitoring methotrexate side effects early in treatment
Part of Brain & nervous system, Cancer clinical trials.
This trial checks how well methotrexate is tolerated in people with primary central nervous system lymphoma. It aims to catch early signs of toxicity to help manage side effects better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary central nervous system lymphoma (lymphoma that starts in the brain or spinal cord).
- You are about to start high-dose methotrexate treatment (more than 500 mg per square meter of body surface) as your first treatment.
- You understand the study and have signed a consent form.
- You have health insurance through a social security plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This trial tests a combination of four chemotherapy drugs (Rituximab, Methotrexate, Temozolomide, and Thiotepa) as the first treatment for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma. It aims to see if this regimen is safe and effective for patients who have not had any prior systemic therapy.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.